Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Vectura and KingYork Form China Respiratory JV

publication date: May 13, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Vectura, a UK maker of inhaled therapies, has established a China JV with two partners: Tianjin KingYork Group Company, a specialist in corticosteroid products, and Zendex Bio Strategy, a Hong Kong private equity investor. The JV, which will be named Tianjin Kinnovata Pharmaceutical Company, will use Vectura’s Clickhaler and Duohaler dry powder inhaler technology platforms to bring treatments for asthma and chronic obstructive pulmonary disease (COPD) to China and the larger Asian region. More details....

Stock Symbol: (LSE: VEC)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...